Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Active negotiation
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
For the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids, or who have experienced a relapse during corticosteroid taper.
Last updated September 2, 2026
Maviret (glecaprevir/pibrentasvir)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
For the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and pediatric patients 3 years of age and older and weighing ≥12 kg.
Last updated August 31, 2026
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal emoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH)
Last updated August 28, 2026
Status:
Under consideration for negotiation
Manufacturer:
Eli Lilly Canada Inc.
Indication:
For once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus: As monotherapy when metformin is inappropriate due to contraindication or intolerance. In combination with: metformin, or metformin and a sulfonylurea, or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i), or basal insulin with or without metformin.
Last updated August 28, 2026
Status:
Under consideration for negotiation
Manufacturer:
BioMarin Pharmaceutical Inc.
Indication:
To increase linear growth in patients with achondroplasia who are 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Last updated August 28, 2026
Status:
Concluded without agreement
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
For the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained greater than or equal to 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering greater than or equal to 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.
Last updated August 26, 2026
Status:
Negotiation on hold (manufacturer-initiated hold)
Manufacturer:
UCB Canada Inc.
Indication:
For the treatment of adult patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic therapy.
Last updated August 24, 2026
Status:
Active negotiation
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
In combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II-III early breast cancer at high risk of recurrence- In pre- or perimenopausal women, or men, the aromatase inhibitor should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
Last updated August 21, 2026
Status:
Under consideration for negotiation
Manufacturer:
GlaxoSmithKline Inc.
Indication:
as add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA)
Last updated August 20, 2026
Imdelltra (Active ENP) (tarlatamab)
Status:
Active negotiation
Manufacturer:
Amgen Canada Inc.
Indication:
For the treatment of adult patients with small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Last updated August 18, 2026